例如:"lncRNA", "apoptosis", "WRKY"

MTAP-deficiency could predict better treatment response in advanced lung adenocarcinoma patients initially treated with pemetrexed-platinum chemotherapy and bevacizumab.

Sci Rep. 2020 Jan 21;10(1):843
Wang Jing 1 , Hui Zhu 2 , Wenjuan Liu 3 , Xiaoyang Zhai 2 , Hairong Tian 2 , Jinming Yu 4
Wang Jing 1 , Hui Zhu 2 , Wenjuan Liu 3 , Xiaoyang Zhai 2 , Hairong Tian 2 , Jinming Yu 4
+ et al

[No authors listed]

Author information
  • 1 The First Affiliated Hospital of Zhengzhou University, Department of Radiation Oncology, Zhengzhou, 450001, Henan Province, China.
  • 2 Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Department of Radiation Oncology, Jinan, 250117, Shandong Province, China.
  • 3 Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Shandong Provincial Key Laboratory of Radiation Oncology, Cancer Research Center, Jinan, 250117, Shandong Province, China.
  • 4 The First Affiliated Hospital of Zhengzhou University, Department of Radiation Oncology, Zhengzhou, 450001, Henan Province, China. sdyujinming@163.com.

摘要


To investigate the predictive value of methylthioadenosine phosphorylase (MTAP) on treatment response and survival in advanced lung adenocarcinoma. MTAP expression was detected by immunohistochemistry. Treatment response and survival were compared according to MTAP expression level. The results indicated MTAP-low expression was observed in 61.2% (101/165) of all patients. The objective response rate and disease control rate improved in the MTAP-low group (64.4% vs 46.9%, p = 0.035; 92.1% vs. 79.7%, p = 0.03; respectively). The median progression-free survival and survival time in the MTAP-low group were significantly lower than that in the MTAP-high group (8.1 vs. 13.1 months, p = 0.002; 22 vs. 32 months, p = 0.044). Multivariate analysis demonstrated that brain metastasis (HR 1.55, p = 0.046), thoracic radiation (HR 0.52, p = 0.026), and MTAP-low expression (HR 1.36, p = 0.038) were independent factors on survival. It is concluded that MTAP-low expression could predict improved treatment response but worsened survival in advanced lung adenocarcinoma.